Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits
E. Schmitz, D. van de Kerkhof, D. Hamann, J. V. van Dongen, P. Kuijper, L. Brunsveld, V. Scharnhorst, M. Broeren•July 1, 2016•43 citations
Chat with this paper
Extract insights, manage references, and accelerate your research
Continue your research
– It's free
Abstract
Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.